Profectus begins Phase I trial of rVSV-vectored HIV-1 vaccine.
M2 PHARMA-January 5, 2012-Profectus begins Phase I trial of rVSV-vectored HIV-1 vaccine(C)2012 M2 COMMUNICATIONS
5 January 2012 - Profectus BioSciences Inc, a US-based vaccine developer, said that, as of 27 December 2011, 20 volunteers have been immunised as part of its Phase I trial designed to asses the safety and immunogenicity of a recombinant vesicular stomatitis virus (rVSV)-vectored HIV vaccine.
The new rVSV vector, expressing the HIV-1 gag protein, is being assessed in a study partly-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study is being conducted by the NIAID-funded HIV Vaccine Trials Network (HVTN) under a protocol designated HVTN 090.
The Phase I, placebo-controlled, dose-escalation study will enrol 60 HIV-uninfected adults and will evaluate the safety and immunogenicity of increasing doses of the rVSV HIV-1 gag vaccine.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 5, 2012|
|Previous Article:||Prana gets FDA nod to initiate study of PBT2 in Huntington's disease.|
|Next Article:||Basilea to seek European approval for antibiotic ceftobiprole in H2 2012.|